Mohammad Ali , Shahid Ud Din Wani , Mubashir Hussain Masoodi , Nisar Ahmad Khan , H.G. Shivakumar , Riyaz M. Ali Osmani , Khalid Ahmed Khan
{"title":"新冠肺炎大流行对癌症患者及其治疗的全球影响：系统综述。","authors":"Mohammad Ali , Shahid Ud Din Wani , Mubashir Hussain Masoodi , Nisar Ahmad Khan , H.G. Shivakumar , Riyaz M. Ali Osmani , Khalid Ahmed Khan","doi":"10.1016/j.ccmp.2022.100041","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>At a global level, the COVID-19 disease outbreak has had a major impact on health services and has induced disruption in routine care of health institutions, exposing cancer patients to severe risks. To provide uninterrupted tumor treatment throughout a pandemic lockdown is a major obstacle. Coronavirus disease (COVID-19) and its causative virus, SARS-CoV-2, stance considerable challenges for the management of oncology patients. COVID-19 presents particularly severe respiratory and systemic infection in aging and immunosuppressed individuals, including patients with cancer.</p></div><div><h3>Objective</h3><p>In the present review, we focused on emergent evidence from cancer sufferers that have been contaminated with COVID-19 and cancer patients who were at higher risk of severe COVID-19, and indicates that anticancer treatment may either rise COVID-19 susceptibility or have a duple therapeutic impact on cancer as well as COVID-19; moreover, how SARS-CoV-2 infection impacts cancer cells. Also, to assess the global effect of the COVID-19 disease outbreak on cancer and its treatment.</p></div><div><h3>Methods</h3><p>A literature survey was conducted using PubMed, Web of Science (WOS), Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), and VIral Protein domain DataBase (VIP DB) between Dec 1, 2019 and Sep 23, 2021, for studies on anticancer treatments in patients with COVID-19. The characteristics of the patients, treatment types, mortality, and other additional outcomes were extracted and pooled for synthesis.</p></div><div><h3>Results</h3><p>This disease has a huge effect on sufferers who have cancer(s). Sufferers of COVID-19 have a greater percentage of tumor diagnoses than the rest of the population. Likewise, cancer and highest proportion is lung cancer sufferers are more susceptible to COVID-19 constriction than the rest of the population.</p></div><div><h3>Conclusion</h3><p>Sufferers who have both COVID-19 and tumor have a considerably elevated death risk than single COVID-19 positive patients overall. During the COVID-19 pandemic, there was a reduction in the screening of cancer and detection, and also deferral of routine therapies, which may contribute to an increase in cancer mortality there in future.</p></div>","PeriodicalId":72608,"journal":{"name":"Clinical complementary medicine and pharmacology","volume":"2 4","pages":"Article 100041"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035683/pdf/","citationCount":"6","resultStr":"{\"title\":\"Global Effect of COVID-19 Pandemic on Cancer Patients and its Treatment: A Systematic Review\",\"authors\":\"Mohammad Ali , Shahid Ud Din Wani , Mubashir Hussain Masoodi , Nisar Ahmad Khan , H.G. Shivakumar , Riyaz M. Ali Osmani , Khalid Ahmed Khan\",\"doi\":\"10.1016/j.ccmp.2022.100041\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>At a global level, the COVID-19 disease outbreak has had a major impact on health services and has induced disruption in routine care of health institutions, exposing cancer patients to severe risks. To provide uninterrupted tumor treatment throughout a pandemic lockdown is a major obstacle. Coronavirus disease (COVID-19) and its causative virus, SARS-CoV-2, stance considerable challenges for the management of oncology patients. COVID-19 presents particularly severe respiratory and systemic infection in aging and immunosuppressed individuals, including patients with cancer.</p></div><div><h3>Objective</h3><p>In the present review, we focused on emergent evidence from cancer sufferers that have been contaminated with COVID-19 and cancer patients who were at higher risk of severe COVID-19, and indicates that anticancer treatment may either rise COVID-19 susceptibility or have a duple therapeutic impact on cancer as well as COVID-19; moreover, how SARS-CoV-2 infection impacts cancer cells. Also, to assess the global effect of the COVID-19 disease outbreak on cancer and its treatment.</p></div><div><h3>Methods</h3><p>A literature survey was conducted using PubMed, Web of Science (WOS), Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), and VIral Protein domain DataBase (VIP DB) between Dec 1, 2019 and Sep 23, 2021, for studies on anticancer treatments in patients with COVID-19. The characteristics of the patients, treatment types, mortality, and other additional outcomes were extracted and pooled for synthesis.</p></div><div><h3>Results</h3><p>This disease has a huge effect on sufferers who have cancer(s). Sufferers of COVID-19 have a greater percentage of tumor diagnoses than the rest of the population. Likewise, cancer and highest proportion is lung cancer sufferers are more susceptible to COVID-19 constriction than the rest of the population.</p></div><div><h3>Conclusion</h3><p>Sufferers who have both COVID-19 and tumor have a considerably elevated death risk than single COVID-19 positive patients overall. During the COVID-19 pandemic, there was a reduction in the screening of cancer and detection, and also deferral of routine therapies, which may contribute to an increase in cancer mortality there in future.</p></div>\",\"PeriodicalId\":72608,\"journal\":{\"name\":\"Clinical complementary medicine and pharmacology\",\"volume\":\"2 4\",\"pages\":\"Article 100041\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035683/pdf/\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical complementary medicine and pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2772371222000225\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical complementary medicine and pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772371222000225","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6
摘要
背景：在全球范围内，新冠肺炎疫情对卫生服务产生了重大影响，并导致卫生机构的日常护理中断，使癌症患者面临严重风险。在疫情封锁期间提供不间断的肿瘤治疗是一个主要障碍。冠状病毒疾病（新冠肺炎）及其致病病毒SARS-CoV-2对肿瘤患者的管理提出了相当大的挑战。新冠肺炎在包括癌症患者在内的老年和免疫抑制患者中表现出特别严重的呼吸道和全身感染。目的：在本综述中，我们重点关注受新冠肺炎污染的癌症患者和严重新冠肺炎风险较高的癌症患者的新证据，并表明抗癌治疗可能会增加新冠肺炎易感性，或对癌症和新冠肺炎产生双重治疗影响；此外，SARS-CoV-2感染如何影响癌症细胞。此外，评估新冠肺炎疫情对癌症及其治疗的全球影响。方法：在2019年12月1日至2021年9月23日期间，使用PubMed、Web of Science（WOS）、Embase、Cochrane图书馆、中国知识基础设施（CNKI）和VIral蛋白质结构域数据库（VIP DB）进行文献调查，以研究新冠肺炎患者的抗癌治疗。提取患者的特征、治疗类型、死亡率和其他额外结果，并合并进行综合。结果：这种疾病对癌症患者有巨大的影响。新冠肺炎患者的肿瘤诊断率高于其他人群。同样，癌症和比例最高的是癌症患者比其他人群更容易感染新冠肺炎。结论：与单个新冠肺炎阳性患者相比，同时患有新冠肺炎和肿瘤的患者的死亡风险显著升高。在新冠肺炎大流行期间，癌症的筛查和检测有所减少，常规治疗也有所推迟，这可能会导致未来癌症死亡率的上升。
Global Effect of COVID-19 Pandemic on Cancer Patients and its Treatment: A Systematic Review
Background
At a global level, the COVID-19 disease outbreak has had a major impact on health services and has induced disruption in routine care of health institutions, exposing cancer patients to severe risks. To provide uninterrupted tumor treatment throughout a pandemic lockdown is a major obstacle. Coronavirus disease (COVID-19) and its causative virus, SARS-CoV-2, stance considerable challenges for the management of oncology patients. COVID-19 presents particularly severe respiratory and systemic infection in aging and immunosuppressed individuals, including patients with cancer.
Objective
In the present review, we focused on emergent evidence from cancer sufferers that have been contaminated with COVID-19 and cancer patients who were at higher risk of severe COVID-19, and indicates that anticancer treatment may either rise COVID-19 susceptibility or have a duple therapeutic impact on cancer as well as COVID-19; moreover, how SARS-CoV-2 infection impacts cancer cells. Also, to assess the global effect of the COVID-19 disease outbreak on cancer and its treatment.
Methods
A literature survey was conducted using PubMed, Web of Science (WOS), Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), and VIral Protein domain DataBase (VIP DB) between Dec 1, 2019 and Sep 23, 2021, for studies on anticancer treatments in patients with COVID-19. The characteristics of the patients, treatment types, mortality, and other additional outcomes were extracted and pooled for synthesis.
Results
This disease has a huge effect on sufferers who have cancer(s). Sufferers of COVID-19 have a greater percentage of tumor diagnoses than the rest of the population. Likewise, cancer and highest proportion is lung cancer sufferers are more susceptible to COVID-19 constriction than the rest of the population.
Conclusion
Sufferers who have both COVID-19 and tumor have a considerably elevated death risk than single COVID-19 positive patients overall. During the COVID-19 pandemic, there was a reduction in the screening of cancer and detection, and also deferral of routine therapies, which may contribute to an increase in cancer mortality there in future.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
